Followers | 223 |
Posts | 23770 |
Boards Moderated | 0 |
Alias Born | 12/30/2012 |
Saturday, December 03, 2016 10:00:38 AM
MF I think you can get your CDL at the American Truck Driving School still. Seems this type of work isn't your cup of tea.
Stock compensation expense, management was $0 and $2,371, respectively, for the three and six months ended June 30, 2016, compared to $93,256 and $109,740 for the six months ended June 30, 2015, respectively. The 2015 amount is comprised of the amortization of restricted common stock issued to our CEO.
Stock compensation expense, other (included in professional and consulting fees) was $344,994 for the six months ended June 30, 2016 and was comprised of the issuance of 5,000,000 restricted shares of common stock issued to an advisor of our board of directors for his appointment. The Company valued the 5,000,000 shares of common stock at $100,000 ($0.02 per share, the market price of the common stock) and recorded the $100,000 as stock compensation expense for the three and six months ended June 30, 2016. The Company also agreed the advisor shall receive a non-qualified stock option to purchase 1,000,000 shares (“Option Shares”) of the Company’s common stock at an exercise price equal to $0.05 per share. Accordingly, the Company recorded $8,694 as stock compensation expense for three and six months ended June 30, 2016. Also included in stock compensation expense, other was the issuance of 1,000 shares of Class B Preferred Stock to Mr. Friedman. The Company valued the shares at $276,300 and recorded $40,000 towards accrued and unpaid fees owed Mr. Friedman and $236,300 as stock compensation expense for the three and six months ended June 30, 2016.
Professional and consulting fees (excluding stock compensation, other) increased to $37,528 and $71,498, respectively, for the three and six months ended June 30, 2016, compared to $19,175 and $39,763 for the three and six months ended June 30, 2015, respectively, and is comprised of the following:
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM